Follicle-stimulating hormone favours mammalian procreation by synthesizing and releasing oestrogen from ovarian follicles. In humans, circulating FSH levels become elevated in response to ovarian failure as the ability to procreate ceases at menopause. It is during the late perimenopause, a period characterized by relatively stable oestrogen and rising FSH levels, that bone loss occurs most rapidly 1, 2 . There is also a sharp increase in visceral adiposity during this life stage, which coincides with the emergence of disrupted energy balance and reduced physical activity 3 . While the subsequent decline in oestrogen explains menopausal bone loss in large part, the effects of oestrogen deprivation on visceral fat and whole-body metabolism remain less clear 4 . We therefore investigated whether, by targeting FSH, we could not only prevent bone loss but also reduce visceral adiposity and improve energy homeostasis.
Follicle-stimulating hormone favours mammalian procreation by synthesizing and releasing oestrogen from ovarian follicles. In humans, circulating FSH levels become elevated in response to ovarian failure as the ability to procreate ceases at menopause. It is during the late perimenopause, a period characterized by relatively stable oestrogen and rising FSH levels, that bone loss occurs most rapidly 1, 2 . There is also a sharp increase in visceral adiposity during this life stage, which coincides with the emergence of disrupted energy balance and reduced physical activity 3 . While the subsequent decline in oestrogen explains menopausal bone loss in large part, the effects of oestrogen deprivation on visceral fat and whole-body metabolism remain less clear 4 . We therefore investigated whether, by targeting FSH, we could not only prevent bone loss but also reduce visceral adiposity and improve energy homeostasis.
Fsh antibody reduces high-fat diet-induced obesity
A polyclonal antibody raised against a 13-amino acid sequence (LVYKDPARPNTQK) of the β -subunit of Fsh (Fshβ ) inhibits ovariectomy-induced bone loss in mice [5] [6] [7] . To establish that the antibody binds to Fshβ and interrupts the interaction of this subunit with its receptor, recombinant mouse Fsh was passed through resin with immobilized Fsh antibody or goat immunoglobulin G (IgG), and fractions immunoblotted with a monoclonal Fsh antibody (Hf2) raised against the corresponding human LVYKDPARPKIQK motif. Extended Data Fig. 1a shows an approximately 50-kDa band in both elution and flowthrough fractions passed through immobilized Fsh antibody, whereas with immobilized goat IgG, all protein appeared in the flow-through fraction. Liquid chromatography with tandem mass spectrometry (LC-MS/MS) of the antibody-immunoprecipitated eluate yielded 10 peptides corresponding to the Fshα -Fshβ chimaera (Extended Data   Fig. 1b, c) , definitively establishing that Fsh was the binding target of the antibody.
We investigated whether the antibody, which was raised against the LVYKDPARPNTQK sequence 6 , could block the interaction of Fsh with the mouse Fsh receptor (Fshr) (Extended Data Fig. 1d ). The crystal structure of the human FSH-FSHR complex (Protein Data Bank (PDB) accession 4AY9) with the motif LVYKDPARPKIQK was used to model mouse Fsh-Fshr interactions (with the motif LVYKDPARPNTQK; Extended Data Fig. 1d) . Notably, the loop from Fshβ (yellow) containing this peptide sequence tucked into a small groove in the Fshr, so that binding of an antibody to this sequence would inevitably block access of Fshβ to its Fshr binding site (Extended Data Fig. 1d (iv) ). To test whether the antibody reversed Fsh-induced inhibition of uncoupling protein 1 (Ucp1), a master regulator of adipocyte beiging and thermogenesis 8, 9 , we used immortalized dedifferentiated brown adipocytes derived from the ThermoMouse (also known as Thermo cells), in which the Ucp1 promoter drives a Luc2-T2A-tdTomato reporter 10 (Extended Data Fig. 1e ). Exogenous Fsh (30 ng ml −1 ) inhibited Luc2 activity in medium devoid of Fsh, and the Fsh antibody reversed this inhibition in a concentration-dependent manner (complete at 1 μ g ml −1 antibody). To determine whether a serum concentration of at least 1 μ g ml −1 would result from a single intraperitoneal injection of 100 μ g antibody, we performed enzyme-linked immunosorbent assays (ELISAs). Mice injected with antibody showed a sharp increase in plasma antibody levels, measured as goat IgG, 2 h after the injection and levels remained at 10 μ g ml −1 or more for up to at least 24 h (t 1/2 = 25.6 h) (Extended Data Fig. 1f) .
Independently, the laboratories of M.Z. and C.J.R. examined the effect of Fsh antibody or goat IgG, injected at 200 μ g per day intraperitoneally, on fat mass in 3-month-old wild-type male and female Menopause is associated with bone loss and enhanced visceral adiposity. A polyclonal antibody that targets the β-subunit of the pituitary hormone follicle-stimulating hormone (Fsh) increases bone mass in mice. Here, we report that this antibody sharply reduces adipose tissue in wild-type mice, phenocopying genetic haploinsufficiency for the Fsh receptor gene Fshr. The antibody also causes profound beiging, increases cellular mitochondrial density, activates brown adipose tissue and enhances thermogenesis. These actions result from the specific binding of the antibody to the β-subunit of Fsh to block its action. Our studies uncover opportunities for simultaneously treating obesity and osteoporosis.
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C57BL/6J mice, which were either pair-fed on, or allowed ad libitum access to, a high-fat diet. Body weight increased over 8 weeks with nearequal food intake in both male and female mice, with no significant difference in either sex between antibody-and goat IgG-treated mice (Fig. 1a) . Quantitative NMR (qNMR) showed a reduction in body fat and an increase in lean mass/total mass (LM/TM) ratio in mice treated with antibody (Fig. 1b) . Data were reproduced using qNMR, dual energy X-ray absorptiometry (DXA) and tissue weight measurements at 7 weeks (Extended Data Fig. 2a-c) . DXA also showed a significant increase in bone mineral density at both 4 and 7 weeks (Extended Data Fig. 2b ). Micro-computed tomography (micro-CT) of distinct thoracoabdominal white adipose tissue (WAT) compartments revealed substantial decreases in visceral and subcutaneous adiposity in antibody-treated mice (Fig. 1c) . Specifically, total (TFV), subcutaneous (SFV) and visceral fat volume (VFV) were all significantly reduced (P ≤ 0.05) in antibody-treated mice than in IgG-treated mice (Fig. 1c) . No difference was observed in interscapular brown adipose tissue (BAT) by weight (Extended Data Fig. 2c ). Similar results were obtained using 8-month-old mice (Extended Data Fig. 3 ) and under thermoneutral conditions at 30 °C (Extended Data Fig. 2d) .
We tested the hypotheses that Fshr-deficient mice would phenocopy the effect of antibody treatment and that the anti-adiposity actions of the Fsh antibody would be attenuated in mice with a genetic Fshr deficiency. IgG-treated male Fshr +/− mice showed reductions in total mass and fat mass measured by qNMR, and in TFV, SFV and VFV measured by micro-CT (Extended Data Fig. 4a, b) . There was no further reduction in any parameter when the Fshr +/− mice were treated with the Fsh antibody (Extended Data Fig. 4a, b) , proving that the antibody acts by suppressing the Fsh signalling axis in vivo. Equally importantly, the fact that haploinsufficient Fshr +/− mice phenocopied the anti-adiposity actions of the Fsh antibody suggests that Fsh is a dominant physiological regulator of fat mass.
In antibody-treated mice, indirect calorimetry using metabolic cages showed increases in energy expenditure and oxygen consumption (VO 2 ), which were accompanied by increased physical activity parameters, including X-beam breaks and walking distance and speed (Extended Data Fig. 2e ). Independently performed penalized spline (p-Spline) regression showed that physical activity, mainly consisting of walking (not running), did not contribute to the increased energy expenditure (Extended Data Fig. 2e) . Specifically, energy expenditure due to physical activity (A-EE (PA)) did not differ between antibodyand IgG-treated groups. Instead, mice displayed an elevated daytime resting energy expenditure (R-EE), which corresponded to the noted trend (P = 0.08) in resting metabolic rate (RMR) on p-Spline regression. The latter findings together suggest that antibody-induced beiging, rather than physical activity, contributes to thermogenesis and leanness, consistent with other studies 11, 12 . This is fully consistent with antibody-induced increases in Ucp1 RNA and protein in both BAT and WAT, as noted below.
We explored known links of physical activity with endocrine mediators of beiging or leanness, which can also affect bone mass [13] [14] [15] . Groups of mice fed on a high-fat diet were injected with antibody or IgG (200 μ g per mouse per day) for 7 weeks, after which half of each group received the tyrosine hydroxylase inhibitor α-methyl-p-tyrosine (AMPT). Plasma noradrenaline levels did not differ significantly between the IgG-and antibody-treated groups either without or following AMPT treatment (Extended Data Fig. 2f ). Likewise, plasma irisin levels were indistinguishable between IgG-and antibody-treated mice (Extended Data Fig. 2g) , and meteorin-like (Metrnl) remained undetectable in the plasma of both groups.
Both glucose tolerance testing (GTT) and insulin tolerance testing (ITT) showed no improvements after antibody treatment (Extended Data Fig. 2h, i) . Consistent with this, plasma C-peptide, adiponectin and leptin levels were unchanged (Extended Data Fig. 2j ). Circulating total cholesterol and free fatty acids were also unchanged, but there was a marginal increase in plasma triglycerides in antibody-treated mice (Extended Data Fig. 2k ). Antibody treatment also did not affect serum oestradiol (E 2 ) levels (Extended Data Fig. 2l ).
Fsh antibody reduces adiposity in ovariectomized mice
The perimenopausal transition is associated with increases in total body fat and decreases in energy expenditure and physical activity, all of which impact quality of life 3 . This clinical phenotype has often been documented in rodents post-ovariectomy, as well as in chronic hypooestrogenaemic models, such as in female Esr1 −/− (also known as Erα , although in our hands, female Fshr −/− mice are not obese. Although genetic Fshr deficiency does not seem to protect against the pro-adiposity effects of severe chronic hypo-oestrogenaemia in female mice, we investigated whether acute suppression of Fsh by a Fsh antibody can, through parallel mechanisms, not only attenuate bone loss 6 but also reduce body fat and improve energy homeostasis. Clinically, this is important during the late perimenopause, when the onset of central adiposity is accompanied by relatively stable oestrogen and increasing Fsh levels 1 . We pair-fed female mice with normal chow, so that their food intake was near-identical over 8 weeks of treatment with Fsh antibody or IgG given intraperitoneally after an ovariectomy or a sham operation. Unlike mice fed on a high-fat diet (Fig. 1a) , these mice on normal chow did not show an increase in total body weight over time (Extended Data Fig. 5a ). However, antibody-treated, sham-operated mice showed a reduction in body weight compared to IgG-injected mice (see Source Data for Extended Data Fig. 5a ; compare with Extended Data Fig. 6a) . Quantitative NMR showed a reduction in fat mass and increase in LM/TM after antibody treatment in both the sham-operated and ovariectomized groups (Fig. 2a) . Antibody treatment also reduced TFV, VFV and SFV in both groups (Fig. 2b) . Furthermore, osmium micro-CT revealed a decrease in marrow adipose volume in antibody-treated mice (Fig. 2c) . Ovariectomy resulted in an expected increase in plasma Fsh levels (Extended Data Fig. 5b ). To ensure that Fsh was blocked effectively despite these increased levels, we used 200 or 400 μ g per mouse per day of antibody to treat the ovariectomy group, as opposed to 100 μ g per mouse per day for the sham-operated group. Notably, although Fsh was bound to antibody (Extended Data Fig. 1a) , total plasma Fsh levels (measured by ELISA) were 
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not significantly different between antibody-and IgG-treated mice (Extended Data Fig. 5b ), confirming previous data 6 . Also, while serum oestrogen levels trended to be lower in the antibody-treated group, there was no significant difference from the IgG-treated group, as noted previously 6 (Extended Data Figs 2l and 5b). We found it interesting that sham-operated mice and ovariectomized mice were equally responsive to antibody treatment (Fig. 2) . We therefore repeated the study using 3-month-old C57BL/6J mice that were either pair-fed or given normal chow ad libitum (see Methods; Extended Data Indirect calorimetry showed that the Fsh antibody enhanced active energy expenditure and reduced respiratory quotient in sham-operated or ovariectomized mice (Extended Data Fig. 5c ). These thermogenic responses were not associated with significant increases in parameters of physical activity; instead, there was an unexplained decrease in walking distance in the ovariectomized antibody-treated group (Extended Data Fig. 5c ). Likewise, a marginal increase in active energy expenditure was noted in antibody-treated wild-type mice on normal chow with no change in physical activity (Extended Data Fig. 6g ). Overall, therefore, physical activity did not contribute to antibody-induced thermogenesis, or indeed, leanness in ovariectomized or wild-type mice on normal chow. There were no differences in plasma levels of glucose, cholesterol, triglyceride or free fatty acids between IgG-and antibody-treated groups on normal chow (Extended Data Fig. 5d ).
Blocking adipocyte Fshr induces Ucp1 expression
Fshr cDNA and protein have been identified in fat tissue and adipocytes 19, 20 , as well as on osteoclasts and mesenchymal stem cells 5, 6 . Here, we have Sanger-sequenced full-length Fshr cDNA from primary mouse mesenchymal stem cells derived from ear lobes (MSC-ad) and 3T3.L1 cells (Extended Data Fig. 7a ). The Fshr protein, which we confirm through immunostaining of inguinal and visceral WAT and BAT (Fig. 3a) , is signalling efficient and functional in its ability to inhibit cAMP (Fig. 3b) and to stimulate the lipogenic genes Fas and Lpl (Extended Data Fig. 7b ). However, in contrast to its coupling with G s proteins in ovarian follicular cells, the adipocyte Fshr couples to G i proteins 5, 20 . Thus, in differentiated 3T3.L1 adipocytes, whereas Fsh abrogated the increase in cAMP triggered by the Arb3 agonist CL-316,243, this inhibition was reversed in the presence of the G i inhibitor pertussis toxin (Fig. 3b) .
As the increase in cAMP induced by Arb3 signalling stimulates Ucp1 21 , we investigated whether Fsh inhibited this induction of Ucp1 using Thermo cells (Extended Data Fig. 1e ). Experiments in the presence of serum, which contains Fsh at 15-40 ng ml −1 (ref. 22) , showed that the antibody (1 μ g ml ), establishing Fsh specificity (Fig. 3c , compare with Extended Data Fig. 1e ). We implanted Thermo cells into both flanks of 3-month-old nu/nu mice and injected IgG or antibody (200 μ g per mouse per day) for 8 weeks. A marked increase in Luc2 radiance was noted upon injection of d-luciferin (Fig. 3d) . For confirmation, we examined tdTomato fluorescence (red) in frozen sections of inguinal WAT (iWAT). Consistent with the increase in Luc2 radiance, antibody-treated mice showed a marked increase in tdTomato expression (Fig. 3e) . Together, the data suggest that the antibody, by blocking the action of Fsh on the Fshr, activates Ucp1.
Fsh antibody triggers beiging of white adipocytes
To determine whether the Fsh antibody induces Ucp1-rich beige-like adipose tissue in vivo, wild-type mice pair-fed on high-fat diet were injected with antibody or IgG. Antibody-treated mice displayed marked reductions in adipocyte area and perimeter in sections of inguinal fat pads, consistent with adipocyte beiging 23 ( Fig. 4a) . Furthermore, there was a marked increase in Ucp1 immunolabelling both in iWAT and BAT (Fig. 4b, c) . This was accompanied at 1 or 3 months with increases in the expression of browning genes in iWAT 24, 25 ( Fig. 4d and Extended Data Fig. 8 ). Increases were also noted in expression of Ucp1, Cidea, Cebpa and Vegfa in BAT at 1 month, commensurate with the early activation of the thermogenic gene program (Fig. 4d and Extended Data Fig. 8) .
Faithfully phenocopying the effect of antibody treatment, subcutaneous WAT from Fshr +/− mice treated with IgG showed evidence of smaller, beige-like adipocytes with more intense Ucp1 immunostaining (Extended Data Fig. 4c ). This effect was not enhanced by antibody injections into Fshr +/− mice, again confirming the specificity of the Fsh antibody (Extended Data Fig. 4c ). We are currently uncertain whether Fsh antibody-induced beige adipocytes are derived from a committed adipogenic precursor or from the conversion of mature white adipocytes, or represent a combination of both mechanisms 26, 27 . As a complementary in vivo test for beiging, we imaged SV129 ThermoMice (Fig. 5) , in which a transgenic Ucp1 promoter drives the Luc2-T2A-tdTomato reporter 10 (Extended Data Fig. 1e ). ThermoMice were pair-fed on a high-fat diet and injected with antibody or IgG (200 μ g per mouse per day). We measured Luc2 radiance from both ventral and dorsal surfaces for optimal visualization of inguinal (WAT-rich plus testes) and interscapular (BAT-rich) regions, respectively. Control non-transgenic mice injected with d-luciferin showed no emitted radiance. Antibody treatment triggered marked increases in Luc2 radiance, prominently in the inguinal region, at 8 weeks (Fig. 5a ). These increases were equally pronounced with a short, 2.5-week treatment 
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under thermoneutrality (30 °C) ( Fig. 5b ; also see Extended Data Fig. 2d ). These data together confirm that antibody treatment triggers beiging, which does not result from environmental cold exposure.
Beiging is associated with an increase in mitochondrial density 28, 29 . We used the PhAM excised mouse, in which a fluorescent protein from the octocoral Dendronephthya, Dendra2, is fused to a Cox8 mitochondrial targeting signal, yielding mito-Dendra2 (Fig. 5c) 
30
. Frozen sections of subcutaneous WAT (sWAT), visceral WAT (vWAT) and BAT from antibody-treated PhAM excised mice (4 weeks) showed a marked increase in fluorescence, and smaller, more condensed, adipocytes in WAT (Fig. 5c ). These data show that Fsh blockade induces mitochondrial biogenesis, which is consistent with Ucp1 activation.
Discussion
The long-held belief that pituitary hormones act solely on master targets was first questioned by the identification of G-protein-coupled 
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receptors for thyroid-stimulating hormone (Tsh), Fsh, Acth, oxytocin and vasopressin on bone cells 5, [31] [32] [33] . These evolutionarily conserved hormones and their receptors have primitive roles, and exist in invertebrate species as far down as coelenterates. It is not surprising, therefore, that each such hormone has multiple hitherto-unrecognized functions in mammalian integrative physiology, and hence, becomes a potential target for therapeutic intervention.
Here, we have confirmed in two laboratories that blocking the access of Fsh to its receptor using an epitope-specific polyclonal antibody results not only in increased bone mass 6 , but also in a marked reduction in adiposity, coupled with the production of mitochondria-rich, Ucp1-high thermogenic adipose tissue. Fsh inhibits Ucp1 expression by reducing cAMP levels, with the antibody causing a sharp, timedependent increase in Ucp1 in both BAT and WAT. The latter effects, best observed in the ThermoMouse, are associated with alterations in cell morphology, gene expression, and mitochondrial biogenesis that are all consistent with adipocyte beiging.
The use of anti-obesity agents, consisting mainly of those that reduce appetite or inhibit nutrient absorption, is compromised by issues of poor efficacy and unacceptable side effects 34 . Thus, the therapeutic armamentarium for obesity currently pales in comparison with those for other public health hazards of similar or lesser magnitudes, such as hypertension, diabetes and osteoporosis. Among targets that induce beige adipose tissue, the Arb3 pathway with its numerous downstream molecules, prominently CEBPB and PRDM16, are best characterized 24, 25, 34, 35 , but agents that modulate this pathway are not sufficiently well developed to be tested in people 34 . Moreover, potential targets, such as C/EBPβ and PPARG, are expressed ubiquitously and during growth and development, which makes tissue specificity an issue.
Previous human studies and particularly the Study of Women's Health Across the Nation (SWAN), an observational cohort of pre-, peri-and postmenopausal women followed for a decade, have suggested that a phase of rapid bone loss ensues two to three years before the onset of menopause, when FSH levels are rising and oestrogen levels are relatively stable 1, 2 . Furthermore, even after the onset of menopause, oestrogen replacement therapy does not always suppress serum FSH levels into the premenopausal range 36 , and women often continue to lose bone and further accrue visceral fat. Our study supports these findings, but more importantly provides mechanistic insights into the clinical problem of peri-and postmenopausal weight gain and disrupted energy balance 3, 4 . With that said, high FSH levels during puberty in both sexes have been reported to coincide with increases in thermogenic BAT. This apparent discrepancy may arise from concurrent increases in sex steroids, specifically androgens, which are known to enhance BAT activity 37 . In view of evidence that our polyclonal Fsh antibody induces WAT beiging and reduced adiposity, we have gone on to develop a monoclonal antibody, Hf2, to a corresponding human FSHβ epitope (LVYKDPARPKIQK); this differs by two amino acids from the mouse epitope. We find that Hf2 binds both human and mouse FSHβ , and its injection into mice on a high-fat diet phenocopies the effects of the polyclonal antibody in not only reducing subcutaneous and visceral fat, but also inducing beiging (Extended Data Fig. 9) .
A humanized Hf2 or its equivalent may not only be efficacious in reducing visceral and subcutaneous fat in people, but might also provide benefit for certain medical conditions associated with visceral adiposity, such as metabolic syndrome, cardiovascular disease, cancer, diabetes, and polycystic ovarian syndrome 38, 39 . Certain of these complications are thought to arise from proinflammatory cytokines, including IL-6 and TNFα , which could additionally benefit from known effects of lowering FSH 40 . Finally, in view of concurrent osteoprotection 6 , we envisage a potential role for an FSH-blocking agent in treating both postmenopausal osteoporosis and obesity. . It is important for bone and fat assays to use the fully glycosylated form, owing to sub-optimal actions of the hypoglycosylated glycoform 41 . Immunoprecipitation. Recombinant mouse Fsh (Fshα -Fshβ chimaera, 2 μ g) was passed through resin (Pierce Co-Immunoprecipitation Kit, 26149, Thermo Scientific) with immobilized Fsh antibody or goat IgG. Elution, flow-through, and consecutive wash fractions were collected and immunoblotted with a monoclonal Fsh antibody (Hf2) (generated by GenScript). Mass spectrometry. The immunoprecipitated eluate (from above) was reduced (DTT, Sigma), alkylated (iodoaceteamide, Sigma), and trypsinized (trypsin, Promega). Peptides were analysed by reversed phase (12 cm/75 μ m, 3 μ m C 18 beads, Nikkyo Technologies) LC-MS/MS (Ultimate 3000 nano-HPLC system coupled to Q-Exactive Plus mass spectrometer, Thermo Scientific). Peptides were separated using a gradient increasing from 6% buffer B/94% buffer A to 50% buffer B/50% buffer A in 34 min (buffer A: 0.1% formic acid; buffer B: 0.1% formic acid in 80% acetonitrile) and analysed in a combined data dependent (DDA)/parallel reaction monitoring (PRM) experiment 42 . Six Fsh peptides were targeted. Tandem MS spectra were recorded at a resolution of 17,500 with m/z of 100 as the lowest mass. Normalized collision energy was set at 27, with automatic gain control (AGC) target and maximum injection time being 2 × 10 5 and 60 ms, respectively. Tandem MS data were extracted and queried against a protein database containing the Fshα -Fshβ chimaera sequence concatenated with an Escherichia coli background database and known common contaminants 43 using Proteome Discoverer 1.4 (Thermo Scientific) and MASCOT 2.5.1 (Matrix Science). Acetyl (Protein N-term) and Oxidation (M) were chosen as variable modifications while all cysteines were considered carbamidomethylated. 10 ppm and 20 mDa were used as mass accuracy for precursors and fragment ions, respectively. Matched peptides were filtered using 1% false discovery rate calculated by Percolator 44 and, in addition, required that a peptide was matched as rank 1 and that precursor mass accuracy was better than 5 ppm. The area of the three most abundant peptides per protein 45 was used to estimate approximately the abundance of matched proteins. Computational modelling. The crystal structure of the human FSH in complex with the entire ectodomain of the human FSHR was used as the template (PDB code 4AY9) for comparative modelling 46 . The sequence of the epitope on mouse Fshβ differs by only two amino acids (DLVYKDPARPKIQK→ DLVYKDPARPNTQK). Several models of the modified Fshβ epitope were constructed using ICM software 47 . Restrained minimization was carried out to remove any steric clashes. The final model was selected on the basis of the lowest Cα r.m.s.d. value after superimposition on the template structure (0.2 Å). The structure of the Fshr resembles a right-hand palm, with the main body as the palm and the protruding hairpin loop as the thumb 46 . The Fshβ binds in the small groove generated between the palm and the thumb. The electrostatic surfaces generated reveal a complementary surface charge between the Fshr and Fshβ . Mice. Colonies of male and/or female wild-type C57BL/6J mice, nu/nu mice, male Fshr +/− mice, male ThermoMice and male PhAM excised mice, originally obtained from The Jackson Laboratory, were maintained in-house at Icahn School of Medicine at Mount Sinai and/or Maine Medical Center Research Institute. Mice were subjected to standard 12-h light-dark cycles (6 am to 6 pm) and fed as below. For thermoneutrality experiments, mice were housed in temperature-controlled cages (30 °C). All protocols were approved by the Institutional Animal Care and Use Committees of the respective institutions. Pharmacokinetics. Three-month-old wild type C57BL/6J mice (n = 15) were injected intraperitoneally with a single dose of antibody (100 μ g per mouse), with groups of three mice being killed at 0, 2, 6, 12 or 24 h. Collected plasma was subject to in-house ELISA, in which two rabbit anti-goat IgGs, one of which was labelled with HRP (HRP-IgG from Jackson ImmunoResearch, Cat. # 305-035-046 and unlabelled IgG from Thermo Scientific, # 31133), were used to sandwich-capture goat IgG. Feeding. Depending on the experiment, 3-, 6-or 8-month-old C57BL/6J mice were pair-fed or allowed ad libitum access to a high-fat diet (DIO Formula D12492, 60% fat; Research Diets, Inc.) or regular chow (Laboratory Rodent Diet 5001; LabDiet) for up to 8 weeks, during which cumulative food intake was measured near-daily, in addition to measurements of body weight around twice per week. For pair-feeding, the amount of chow consumed ad libitum by the IgG group was given to the antibody-treated group. For the ad libitum protocol used at Maine Medical Center, both groups were allowed free access to food, with the leftover chow being counted to determine food intake. For specific experiments (Extended Data Fig. 6d-f) performed at Mount Sinai, the antibody-treated group was allowed ad libitum access to food and the same amount of chow was given to the IgG group, with the leftover chow being counted to determine the food intake of the IgG group. Antibody was injected at doses between 100 and 400 μ g per mouse as noted in the individual figure legends. Numbers of mice per group are indicated in the figure legends. Measurement of body fat. Several complementary approaches, namely quantitative nuclear magnetic resonance (qNMR), microcomputed tomography (micro-CT), dual energy X-ray absorptiometry (DXA), osmium micro-CT for bone marrow fat quantification, and tissue weight measurements, were used to examine total body fat, as well as fat volume or weight in different adipose tissue compartments. Quantitative NMR. For qNMR, live mice were placed into a thin-walled plastic cylinder, with freedom to turn around. An Echo3-in-1 NMR analyser (Echo Medical) was used to measure fat, lean and total mass, according to the manufacturer's instructions. Micro-computed tomography. For micro-CT, we followed the protocol described in ref. 48 . VivaCT-40 (Scanco AG) with a detector size of 1,024 × 256 pixels was used for imaging fat and measuring fat volume in thoracolumbar compartments. Mice were anaesthetized by purging the chamber with 5% isoflurane and O 2 for 5-10 min (X.E.G.) or with Avertin (C.J.R.) and positioned with both legs extended. The torso of each mouse was scanned at an isotropic voxel size of 76 μ m (45 kV, 133 μ A) and a 200-ms integration time. Two-dimensional grey scale image slices were reconstructed into a 3D tomogram, with a Gaussian filter (σ = 0.8, support = 1) applied to reduce noise. Scans were reconstructed between the proximal end of L1 and the distal end of L5. The head and feet were not scanned or evaluated because of the relatively low adiposity in these regions, and to allow a decrease in scan time and radiation exposure for the animals. Regions of fat were manually traced and thresholded at 5% maximum grayscale value. The high resolution of this method allows the imaging of both sWAT and vWAT. An automated algorithm was used to quantify the volume of sWAT and vWAT using previously described methods 49, 50 . Dual energy X-ray absorptiometry. BMD and body fat measurements were performed using a Lunar Piximus DXA, with a precision of < 1.5% 51 . Anaesthetized mice were subject to measurements, with the cranium excluded. The instrument was calibrated each time before use by employing a phantom per the manufacturer's recommendation. Osmium quantification of marrow fat. Osmium staining for marrow fat was performed in collaboration with the Small Animal Imaging Core and the Physiology Core at Maine Medical Center Research Institute, using previously published methods 52 . Briefly, tibias were isolated, fixed with 10% formalin for 24 h, washed, and then decalcified for 14 days in EDTA. Upon further washing, bones were stained for 48 h in 1% osmium tetraoxide. Following subsequent washes, bones were scanned in PBS with an energy level of 55 kVp, and intensity of 145 μ A using the VivaCT-40 (Scanco AG). The integration time was set to 500 ms at a maximum isotropic voxel size of 10.5 μ m at a high-resolution setting. Two voxels of interest (VOIs) were selected as shown in Fig. 2c . Indirect calorimetry. Indirect calorimetry was performed, as described previously 49 , using the Promethion Metabolic Cage System (Sable Systems) located in the Physiology Core of Maine Medical Center Research Institute. Data acquisition and instrument control were performed using MetaScreen software (v.2.2.18) and raw data processed using ExpeData (v.1.8.2) (Sable Systems). An analysis script detailing all aspects of data transformation was used. The study consisted of a 12-h acclimation period followed by a 72-h sampling duration. Each metabolic cage in the 16-cage system consisted of a cage with standard bedding, a food hopper, water bottle, and 'house-like enrichment tube' for body mass measurements, connected to load cells for continuous monitoring, as well as 11.5-cm running wheel connected to a magnetic reed switch to record revolutions. Ambulatory activity and position were monitored using XYZ beam arrays with a beam spacing of 0.25 cm. From these data, mouse pedestrial locomotion and speed within the cage were calculated. Respiratory gases were measured using the GA-3 gas analyser (Sable Systems) equipped with a pull-mode, negative-pressure system. Air flow was measured and controlled by FR-8 (Sable Systems), with a set flow rate of 2,000 ml/min. Oxygen consumption (VO 2 ) and carbon dioxide production (VCO 2 ) (not shown) were reported in ml per minute. Water vapour was measured continuously and its dilution effect on O 2 and CO 2 were compensated mathematically in the analysis stream. Energy expenditure (EE) was calculated using: kcal/h = 60* (0.003941* VO 2 + 0.001106* VCO 2 ) (Weir Equation) and respiratory quotient (RQ) was calculated as VCO 2 /VO 2 . Ambulatory activity and wheel running were determined simultaneously with the collection of the calorimetry data. We used two independent methods to derive resting energy expenditure (REE) and active energy expenditure from the time-dependent calorimetry and activity data. First, we determined REE as the average EE of 30-min intervals of no activity, and active EE as the average EE of 15 min of the most active states. Second, we used penalized spline regression to estimate the continuous REE (or resting metabolic rate (RMR)) ARTICLE RESEARCH and active EE related to physical activity (AEE (PA)), using four equidistant knots per day in the spline function and optimizing the activity-related preprocessing parameters with respect to the regression residuals 53, 54 . Sleep hours were determined as any inactivity lasting greater than 40 s or more. This latter analysis provided us with an independent verification for a lack of relationship between physical activity and EE 53, 54 Extended Data Fig. 2m . ITT and GTT. Mice were tested after 4 weeks of treatment with antibody or IgG for glucose and insulin tolerance. For GTT, mice were placed in a clean cage with water and starved overnight (16 h), following which glucose (1 g/kg) was administered intraperitoneally, and blood glucose levels measured at 0, 15, 30, 60, 90 and 120 min post-injection using the OneTouch Ultra Glucometer (LifeScan, Inc.) per manufacturer's instructions. For ITT, antibody-or IgG-treated mice were fed ad libitum and injected intraperitoneally with insulin (1 U/kg). Glucose levels were measured at 0, 15, 30, 45, 60 and 120 min after injection. In vivo luciferase imaging. In the ThermoMouse, a luciferase reporter construct, Luc2-T2A-tdTomato, is inserted into the Ucp1 locus on the Y chromosome 10 (Extended Data Fig. 1e) . Activation of Ucp1 expression leads to upregulation of Luc2, which can be quantified in vivo by radiance (luminescence) measurements using IVIS Spectrum In vivo Imaging System (Perkin Elmer) following the injection of d-luciferin (10 μ l g -1 ). Three-month-old male ThermoMice were treated with Fsh antibody or goat IgG (200 μ g per day per mouse) for 2.5 (under thermoneutral conditions at 30 °C) or 8 weeks (at room temperature) while being pair-fed on high-fat diet, followed by d-luciferin injection and radiance capture from the ventral and/or dorsal surfaces of the entire body and lower and upper body regions of interest (ROI). In separate experiments, Thermo cells (1.5 × 10 6 ) were implanted into both flanks of nu/nu mice, which were fed on normal chow and injected with antibody (200 μ g per mouse per day) for 8 weeks, following which Luc2 radiance was quantified after d-luciferin. As basal levels of Ucp1 expression can be variable in transgenic mice, and could therefore confound data interpretation, we routinely perform an early time point for radiance capture at 5 min post-d-luciferin. This allows us to evaluate 'basal' Ucp1 expression, and mice whose measured total flux and/or average radiance at the 5-min time point is more than 1 s.d. from the mean of group are excluded. For independent confirmation, frozen sections of resected areas where cells had been implanted were examined for tdTomato fluorescence. Cell lines. We used immortalized dedifferentiated brown adipocytes derived from the ThermoMouse (Thermo cells), in which the Ucp1 promoter drives a Luc2-T2A-tdTomato reporter 10 , provided by S. Kajimura (UCSF). 3T3.L1 cells were purchased from ATCC. Cell lines were not authenticated, nor were they tested for mycoplasma. Histology, immunodetection, qPCR and ELISA. Tissues were subject to haematoxylin & eosin staining or immunocytochemistry by protocols described earlier 55 . Images were captured using the Keyence or Zeiss microscope. Immunocytochemistry for Fshr used standard protocols and an anti-Fshr antibody (Lifespan, Cat. #LS-A4004). tdTomato and mito-Dendra2 fluorescence was examined in frozen, 15-μ m sections. Quantitative PCR was performed using appropriate primer sets using Prism 7900-HT (Applied Biosystems Inc.) 56 . For cAMP measurements, cells were treated for 20 min with Fsh and/or CL-316,243, with or without a 16-h pre-incubation with pertussis toxin (100 ng ml -1 ; European Pharmacopoeia) (in the presence of 0.1 mM IBMX). Cyclic AMP was measured in cell extracts using an ELISA kit (Cayman, 581001). For irisin and metrnl measurements, we used ELISAs (Phoenix, EK-067-29 and R&D, DY7867, respectively). Plasma Fsh and E 2 levels were measured by ELISAs (Biotang, M7581 and M7619, respectively). Noradrenaline levels. Thirty-two mice fed on a high-fat diet were treated with antibody or IgG (200 μ g per mouse per day) for 7 weeks. Half of each group was killed at the outset following blood draw, and the other half was injected with α -methyl-p-tyrosine (AMPT; 250 mg kg -1 ), with a supplementary dose (125 mg kg -1 ) 2 h later. After a further 2 h, both groups were killed following blood draw. Extraction and HPLC were conducted at the Core CTSI Laboratory at Yale Medical School (courtesy: R. Jacobs). Statistics. From preliminary micro-CT data, we found a marked, up to threefold, difference in fat volumes with 4 or 5 mice per group. Using a pre-specified effect size (x 1 − x 2 )/s of 3, a normalized Z-score at α = 0.05 (Z α ) of 1.96, and assuming that standard deviation (S) is half the width of the confidence interval (W)
], 4 mice per group was calculated to be sufficient for 95% statistical significance at 0.8 power (α = 0.05, β = 0.20). Statistically significant differences between any two groups were examined using a two-tailed Student's t-test, given equal variance. P values were considered significant at or below 0.05. Randomization, blinding and exclusion. Mice were randomly picked for injection with IgG or antibody to ensure equal distribution of body weight across the groups. Technicians who generated and analysed micro-CT and qNMR data at Dr. Guo's laboratory at Columbia University and Dr. Buettner's laboratory at Mount Sinai, respectively, were blind to the mouse groups (Figs 1 and 2, Extended Data Figs 3, 4,  6 and 9) . Additionally, the technician at the Mount Sinai Imaging Core Facility who generated data with Thermo mice (Fig. 5) and Thermo cell implants into nu/nu mice (Fig. 3d) was also blind to the mouse groups. Note that the fundamental data were confirmed at Dr. Rosen's laboratory at Maine Medical Center (Extended Data Table 1 ). For experiments with Thermo mice, basal Luc2 measurements following d-luciferin injections were made before sampling. Luc2 radiance at 5 min is expected to be low. We made a pre-specified determination that if Luc2 radiance in a given mouse exceeded 1 s.d. of the mean, that mouse was excluded. One mouse was excluded on the basis of this criterion. Data availability. The authors declare that all data supporting the findings of this study are available within the paper and as Source Data files. Specifically, all Source Data for Figs 1-5 and Extended Data Figs 1-9 is available with the online version of the paper as Excel spreadsheets (for bar graphs) and as a PDF file (for the raw immunoblot scan in Extended Data Fig. 1a ). Extended Data Table 1 attributes specific experimental sets to individual principal investigators. Figure 6 | Fsh antibody reduces body fat in mice fed on normal chow. a-f, Three-month-old C56BL/6J female mice were either pair-fed (a-c) or fed ad libitum (d-f) with normal chow and injected with Fsh antibody or IgG (100 μ g per mouse per day) for 7 and 5 weeks, respectively. For pair-feeding, the amount of chow consumed ad libitum by the IgG group was given to the antibody-treated group. For ad libitum feeding, the antibody-treated group was allowed ad libitum access to food and the same amount of chow was given to the IgG group, with the leftover chow measured to determine food intake of the IgG group (see Methods). A significant increase in food intake by antibody-treated mice was noted in the ad libitum feeding protocol (d). Nonetheless, as with mice on a highfat diet, in either feeding protocol (compare with Fig. 1 and Extended Data Fig. 2) , antibody treatment caused a substantial decrease in total mass (TM), fat mass (FM) and FM/TM and increase in LM/TM on quantitative NMR (b) in mice that were pair-fed. Body weight (a) was also reduced (see Source Data for P values). However, whereas antibody-treated mice consumed substantially more chow than IgG-injected mice, they showed decreases in FM and FM/TM, but did not show a reduction in TM (e) or body weight (d) (also see Source Data for P values). Micro-CT showed profound decreases in thoracoabdominal fat, visualized in representative coronal and transverse sections (red, visceral fat; yellow, subcutaneous fat), and upon quantification of TFV, SFV and VFV (c, f) in both groups (n = 4, 5 or 6 per group for a-f). g, Indirect calorimetry (metabolic cages) showing A-EE, running distance (Wheel Meters), running speed (Wheel Speed), walking distance (Ped Meters), walking speed (Ped Speed) and food intake (n = 4 per group). Two-tailed Student's t-test; * P ≤ 0.05, * * P ≤ 0.01, ^P = 0.069, or as shown.

Extended Data
